Default company panoramic image

GLG Pharma, LLC

Developing the next generation of targeted therapies

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Jupiter, FL, USA
  • Currency USD
  • Founded May 2009
  • Employees 7
  • Website

Company Summary

GLG Pharma, LLC, is developing a series of inhibitors of activated (STAT3) protein covered by issued or pending patents, and licensed from the Moffitt Cancer Center & Research Institute, Tampa FL. GLG Pharma’s therapeutics will treat a wide variety of STAT3 mediated diseases; cancers ($75-80 billion by 2012); psoriasis ($7.3B) with potentially greater efficacy and fewer side effects than existing therapies.


  • Default avatar
    Hector J. Gomez, MD, PHD
    Chief Executive Officer & Founder

    Managed the development of several drugs, 10 of them currently in the market. Examples of major NDA’s are Enalapril (Vasotec) and Lisinopril (Prinivil/Zestril).
    • President and CEO, Transcend Therapeutics, Inc.,
    • VP of Medical Affairs, Vertex Pharmaceuticals
    • Executive Director, Novartis
    • Director and Senior Director, Merck/MSDRL Corporation
    • Chairman, DNAPrint Genomics, Inc.
    • Scientific Advisor, Athena Capital Partners, Inc.

  • Default avatar
    Richard Gabriel, MBA
    Chief Operating Officer & Founder

    Was instrumental in closing and managing over $135 million in contract revenue for Pharm-Eco Laboratories
    • CEO & President of Calix Corporation, parent company to Pharm-Eco Laboratories, Inc.
    • Successfully completed the formation of several genetics, chemistry and pharma JVs, LLCs & spin-offs
    • CEO & President, DNAPrint Genomics, Inc.
    • Assisted in the development of: Amprenavir, Emtricitabine, Altretamine, Zalcitabine
    • Over 30 IND’s/AND

  • Default avatar
    Michael W. Lovell, PhD
    Executive Vice President & Founder

    Assisted over 28 clients with development and commercialization of over 30 products
    • Founder & President, AcraPharm Consulting, Inc., providing CMC management and technical consulting services to pharmaceutical and bio-tech companies.
    • Co-founder and VP, BioDevelopment Laboratories (BDL)
    • Held several key executive and scientific positions at companies such as Arthur D. Little, Abbott Laboratories, G. D. Searle and Bristol-Myers.

  • Default avatar
    Sunanda Singh, MD, PhD
    Director of Cancer Immunology

    • Residency, General Surgery and Plastic and Reconstructive Surgery
    • Private practice for over ten years
    • Advisory Board of Hernando Healthcare Inc.
    • Chief of Staff, Brooksville Regional Hospital and Spring Hill Regional Hospital
    • Clinical interest: skin cancers, melanoma, reconstructive surgery, hand surgery, and wound healing
    • Research interest: include tumor immunology, cancer biology, and transplantation immunology

  • Default avatar
    John J. Whalen, MD
    Chief Medical Officer

    Had overall responsibility or played major role in planning, execution and submission of development programs of eleven approvable NDAs or PLAs.
    • SVP Clinical Research, SCIREX CRO
    • SVP R&D, Alpha Therapeutics
    • VP, Clinical Research at the GHBA (Now Covance)
    • VP, Clinical Development Operations at Medimmune (Division of Astra Zeneca)
    • Director, Clinical Research, MSDRL

  • Default avatar
    Ray Johnson, MBA
    Chief Financial Officer (acting)

    Held positions of CFO/ President with 5 early stage companies in the medical/pharmaceutical industry
    • Has successfully raised over $30M of pre-venture capital for those companies
    • Co-founder/President, Cytonics Corp.
    • President, Atlas Spine, a spine implant company
    • Founder/President of Doyen Medipharm,
    • Vice Chairman of Jupiter’s Economic Development Advisory Board
    • Chairman of the Early Stage Biotech Coalition


  • Default avatar
    McNamara & Carver, P.A.
    Default avatar
    Hanna, Lemar & Morris, CPA's, PA